Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study.

Challenge

While the TAF safety and effectiveness analysis above characterized outcomes in the full TAF-treated cohort, a dedicated effectiveness analysis focusing on virological suppression, ALT normalization, and other key endpoints across the full TARGET-HBV observational cohort was needed to comprehensively document real-world performance.

Solution

The TARGET-HBV cohort was analyzed to characterize the effectiveness of TAF across virological, biochemical, and serological endpoints in the full spectrum of HBV patients receiving usual care, including subgroup analyses by prior treatment history, cirrhosis status, and baseline disease characteristics.

Impact

Providing comprehensive real-world effectiveness documentation for TAF across a broad HBV patient spectrum supports post-authorization regulatory reporting obligations, informs prescriber guidance for real-world clinical decision-making, and establishes benchmark data for future HBV antiviral comparators.